Phase 1 study

Recruiting Phase 1

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 1
Sponsor Immunocore Ltd
Registry number NCT07156136
Started 7 November 2024 Today 16 October 2026 Estimated completion 30 September 2027

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Cancer Research South Australia (CRSA) Adelaide SA Recruiting
Linear Clinical Research ltd. Nedlands Australia Recruiting
Melanoma Institute Australia Wollstonecraft NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 140

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

* HLA-A\*02:01-positive

* Meeting PRAME-positive tumor testing requirements

* Metastatic or unresectable solid tumors

* Have received (or be receiving), relapsed from, be refractory to or intolerant of all therapies

* Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control

Exclusion Criteria:

* Symptomatic or untreated central nervous system metastasis

* Bowel obstruction, perforation, or fistula formation within 3 months prior to the planned first dose of study treatment

* Ongoing ascites or effusion requiring recent drainages

* Significant ongoing toxicity from prior anticancer treatment

* Out-of-range laboratory values

* Clinically significant lung, heart, or autoimmune disease

* Ongoing requirement for immunosuppressive treatment

* Significant secondary malignancy

* Hypersensitivity to study drug or excipients

* Pregnant or lactating

Dates on the record

Started 7 November 2024
Estimated completion 30 September 2027
Registry last updated 25 February 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 25 February 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.